Bioage Labs Inc (BIOA) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bioage Labs Inc   (NASDAQ: BIOA)

Bioage Labs Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Bioage Labs Inc in the second quarter 2026?
Bioage Labs Inc recorded a cumulative net loss of $-94 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -28.99%.

Within the Major Pharmaceutical Preparations industry 114 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2952 to 3011.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 27.18 % 21.06 % -15.81 % -11.56 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -94 -90 -81 -76 -79
Return On Equity (TTM) -28.99 % -29.4 % -27.86 % -25.09 % -25.39 %
BIOA's Total Ranking # 3011 # 2952 # 2562 # 1378 # 2646
Equity (TTM) in Millions 375 379 272 277 295
Seq. Equity Change -1.11 % 39.36 % -1.95 % -5.87 % -5.87 %
Seq. Net Income Change - - - - -

Back to BIOA Management Effectiveness >> BIOA's 5 Years Annual ROE >> Compare BIOA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 115
Sector # 315
Overall # 3011

Return On Equity Statistics
High Average Low
75.79 %
-2.87 %
-155.56 %
(Dec 31 2014)   (Dec 31 2017)



  News about Bioage Labs Inc Return on Equity ROE

Biotech Breakthroughs vs. Financial Fumbles: The Diverging Paths of BioAge Labs and BioAmber Inc.

Navigating Biotech Breakthroughs Amidst Financial Turbulence: BioAge Labs and BioAmber Inc. In an era where the battle against obesity is fought on multiple fronts, BioAge Labs stands at the intersection of innovation and public health. The biotech company is preparing to present preclinical data for its APJ agonist, Azelaprag, during ObesityWeek 2024. This announcement arrives at a time when obesity treatment options are a critical focus for both the healthcare community and the pharmaceutical industry. Promising Developments in Obesity TreatmentThe forthcoming presentations from BioAge Labs will showcase compelling results from studies conducted on obese mice. The research indicates significant weight loss when Azelaprag is combined with various oral appetite suppressants. Moreover, the agonist appears to demonstrate robust results on its own, offering substantial protection against weight gain—a particularly important consideration amid rising obesity rates globally.This dual approach of utilizing Azelaprag, both as a stand-alone treatment and in conjunction with other appetite suppressants, positions BioAge Labs as a key player in the evolving landscape of obesity therapeutics. If these preclinical results translate into successful human trials, it could spearhead new treatment paradigms and carve out a substantial market share in an arena desperately seeking effective solutions.



BIOA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015
Total Equity in Millions 272 323 22 48 46
Y / Y Equity Change -15.81 % 1378.66 % -54.93 % 4.61 % -19.42 %
Net Income in Millions -81 -71 -102 -28 41
Y / Y Net Income Change - - - - -12.95 %
Return On Equity -29.63 % -22.01 % -467.62 % -58.51 % 88.82 %

Back to BIOA Management Effectiveness >> BIOA's 5 Years Annual ROE >> Compare BIOA ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BIOA's' Return on Equity at Yahoo Finance
BIOA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BIOA's Competitors
Subscribers only: Roe for Bioage Labs Inc 's Suppliers
Subscribers only: Return On Equity for BIOA's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-10T09:28:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.